Cannabinoids control spasticity and tremor in a multiple sclerosis model
Neuroinflammation Group, Department of Neurochemistry, Institute of Neurology, University College London
† The Medical Research Council
Human Movement and Balance Unit, National Hospital for Neurology and Neurosurgery
, Queen Square, London, WC1N 3BG, UK
‡ Department of Biomedical Sciences,
Institute of Medical Sciences, University of Aberdeen, Foresterhill , Aberdeen
AB25 2ZD, UK
§ Department of Chemistry, Clemson University, Clemson, South
Carolina 29634-1905 , USA
Multiple Sclerosis Society of Great Britain and Northern
Ireland , 25 Effie Road, London SW6 1EE, UK
Correspondence and requests for materials should be addressed to D.B. (e-mail: D.Baker@ion.ucl.ac.uk).
Chronic relapsing experimental allergic encephalomyelitis (CREAE) is an autoimmune model of multiple sclerosis1. Although both these diseases are typified by relapsing-remitting paralytic episodes, after CREAE induction by sensitization to myelin antigens1 Biozzi ABH mice also develop spasticity and tremor. These symptoms also occur during multiple sclerosis and are difficult to control. This has prompted some patients to find alternative medicines, and to perceive benefit from cannabis use2. Although this benefit has been backed up by small clinical studies, mainly with non-quantifiable outcomes3-7, the value of cannabis use in multiple sclerosis remains anecdotal. Here we show that cannabinoid (CB) receptor agonism using R(+)-WIN 55,212, delta9-tetrahydrocannabinol, methanandamide and JWH-133 (ref. 8) quantitatively ameliorated both tremor and spasticity in diseased mice. The exacerbation of these signs after antagonism of the CB1 and CB2 receptors, notably the CB1 receptor, using SR141716A and SR144528 (ref. 8) indicate that the endogenous cannabinoid system may be tonically active in the control of tremor and spasticity. This provides a rationale for patients' indications of the therapeutic potential of cannabis in the control of the symptoms of multiple sclerosis2, and provides a means of evaluating more selective cannabinoids in the future.
High
doses of delta9-tetrahydrocannabinol THC; (the major psychoactive component of
cannabis) can inhibit the development of CREAE in rodents9, 10, but this has been
attributed to immunosuppression preventing the conditions that lead to the development
of paralysis, rather than to a direct effect on the paralysis itself9, 10. However,
the action of cannabinoids on experimental spasticity and tremor remains uncertain
because there have so far been no behavioural data on the effects of cannabinoids
in animal models relevant to these symptoms of multiple sclerosis.
It
is well established that repeated neurological insults occur during CREAE; these
are associated with increasing primary demyelination and axonal loss in the central
nervous system (CNS)1. However, it was also evident that CREAE animals can develop
additional clinical signs, including unilateral or bilateral fore- and hindlimb
tremor and hindlimb spasticity. These accumulate with disease duration and activity.
Tremor was associated with voluntary limb movements, but in more severe cases
it was persistent at a frequency of 40 Hz (Fig. 1e). Although considerably faster
than encountered in humans (6 Hz), this frequency is consistent with tremor electromyography
in mutant spastic (GlrbSpa) mice11. These animals develop episodes of rapid tremor
and rigidity of the limb and trunk muscles12. However, unlike the GlrbSpa mouse,
spasticity in CREAE mice need not be triggered by sudden disturbance12. The effects
of cannabis are mediated through the CB1, CB2 and putative CB2-like receptors13,
14. CB1 is predominant in the CNS and is the main target for psychoactivity, but
it is also expressed at lower levels in many peripheral tissues. The CB2 receptor
is expressed at high levels on leucocytes, but there is also evidence for limited
CB2 receptor expression in mouse brain4, 13. The administration of a full CB1
and CB2 agonist, R(+)-WIN 55,212 (ref. 8), to post-relapse remission mice resulted
in a rapid (within 1–10 min) amelioration of the frequency and amplitude
of tremor in both the fore- and hindlimbs of CREAE mice. This was visually evident
at 5 mg kg-1 (Fig. 1a–d ; n = 10/10) and 1 mg kg -1 intraperitoneal (i.p.)
(n = 6/6). In addition, THC (10 mg kg-1 intravenous (i.v.)) also ameliorated this
response (n = 5/5). Tremor returned within hours after treatment. As delta9-THC
was observed to be relatively ineffective when injected intraperitoneally (i.p.),
as seen in other studies10, all subsequent compounds were injected intravenously.
Furthermore, as delta9-THC is a partial CB1 agonist but provides more limited
CB2 agonist activity, these results suggest that the effect on tremor is mainly
mediated by the brain CB1 receptor8.
Pretreatment (10 min) of animals with 5 mg kg -1 i.v. of both selective CB1 (SR141716A) (ref. 15) and CB2 (SR144528) (ref. 16) receptor antagonists eliminated the capacity of 5mg kg -1 i.p. R(+)-WIN 55,212 to inhibit tremor (n = 5/5). However animals with residual paresis and mild spasticity became significantly more spastic after such CB receptor antagonism ( Fig. 3). This was associated with uncontrolled leg crossing (Fig. 3c and d) and severe tail spasms. These showed gross curling which is atypical of post-remission animals, in which the tail generally hangs limply (Fig. 3e). Animals also show hindlimb extension (Fig. 3c), including a significant (P < 0.0001) increase in resistance to flexion. This was not observed in vehicle-treated controls (Fig. 3a ). These signs were also not evident in similarly injected normal mice (n = 0/5) or normal-appearing pre-acute EAE animals (hindlimb resistance to flexion 0.159 0.013N compared with 0.206 0.022N in treated mice (n = 12 limbs, P > 0.05) and in animals with paresis/paralysis without evidence of spasticity (n = 0/5 treated with SR141716A and SR144528, n = 0/4 treated with SR141716A or SR144528 alone). When mildly spastic animals without tremor were injected with 5 mg kg-1 i.v. CB1 antagonist, not only did significant hindlimb (P < 0.001; Fig. 3a) and tail spasticity (n = 18/18 , P < 0.001) develop compared with vehicle treated controls (n = 0/6), but forelimb tremor also became evident in 3 out of 10 mice. This suggests a role for CB1 in the control of tremor. After injection of 5 mg kg -1 i.v. CB2 antagonist, some animals (n = 10/14) seemed to show a mild increase in tail spasticity ( P < 0.02) and showed a small but significant ( P < 0.05) increase in resistance to hindlimb flexion. However, when the CB2 antagonist was injected into animals previously made more spastic (P < 0.01) by CB1 antagonism, spasticity increased significantly (P < 0.001) compared with animals treated with SR141716A alone, whereas this was resolved in animals treated with vehicle. This suggests that both CB receptors may control spasticity ( Fig. 3f). However, it is possible that the effects of SR144528 could be mediated by CB2-like (rather than CB2) receptors as previously proposed17, or that at the dose used, SR144528 may have produced additional CB1 antagonism because it has some limited capacity to bind to CB1 (ref. 8). These observations may indicate the continual release of endogenous cannabinoid receptor agonists such as anandamide and 2-arachidonylglycerol which are present within the brain and exhibit neurotransmitter function18.
Alternatively,
or in addition, they may reflect the presence of precoupled, constitutively active
cannabinoid receptors, as there is evidence that SR141716A and SR144528 are both
inverse agonists that are capable of producing inverse cannabimimetic effects
by reducing the proportion of cannabinoid recetors that exist in a precoupled
state8, 15, 16. In comparison to some studies in which the antagonists affected
the exogenous agonists17, the actions of the antagonists seen here were relatively
short-lived ( Fig. 3f). This may reflect the fact that the animals were attempting
to compensate for the antagonist effect, and would be consistent with tonic control
of the endogenous cannabinoid system. These data provide compelling evidence that
CB receptors are involved in the control of spasticity in an environment of existing
neurological damage, and that exogenous agonism may be beneficial.Figure 3 Control
of spasticity by the cannabinoid system. Full legend
Indeed, in mice with significant spasticity, 5 mg kg -1 i.p. R(+)-WIN 55,212 reduced severity both visually ( n = 7/7; Fig. 3g, h and i) and after assessment of resistance to hindlimb flexion (P < 0.001) (Fig. 3a and i). This was also evident with 2.5 mg kg -1 i.p. R(+)-WIN 55,212 (Resistance of flexion of both limbs being reduced (P < 0.05) from 0.384 0.096N to 0.276 0.063N, n = 7, P < 0.05). Similar treatment with 5 mg kg -1 i.p. of the inactive enantiomer S(-)-WIN 55,212 failed to significantly affect the spastic resonse (Fig. 3a). In contrast, 10 mg kg-1 i.v. 9 -THC and 5 mg kg-1 i.v. methanandamide (CB1-selective; Ki for CB1 20 nM and Ki for CB2 815 nM )8 induced a significant (P < 0.001 ) amelioration in spasticity. Coupled with the observations using SR141716A, this may suggest further that CB 1 is a main target for control of spasticity. Currently there are no compounds which are totally CB1 or CB2 receptor specific, but the lack of effect after 10 mg kg-1 i.v. cannabidiol (main non-psychoactive component of cannabis. Ki for CB1 = 4350 nM)8 suggested a subthreshold dose for CB1 stimulation for treatment of spasticity. Using the CB2-selective agonist JWH-133 (1.5 mg kg-1 i.v. Ki for CB1 680 nM and Ki for CB2 3 nM)8, 19 spasticity was reduced both 10 min (P < 0.05) and 30 min (P < 0.001) after injection at a time when 0.05 mg kg-1 i.v. (dose selected to exhibit similar CB1 activity to JWH-133) methanandamide was not active (Fig. 4). It is possible that sedative effects may have contributed (though CB1 receptors) to cannabinoid-mediated effects in these assays, but there was no hypothermia, indicative of 'sedation' after JWH-133 administration (37.1 0. °C (baseline), 37.2 0.4 °C (10 min) 37.1 0.2 °C (30 min)). That non-CB1 receptors may also control spasticity is further indicated by the transient inhibition of spasticity with the endocannabinoid palmitoylethanolamide (Fig. 4). This compound has no significant affinity for CB1 but may have activity for CB2-like receptors8. The involvement of non-CB1 receptors may be definitively resolved through the use of CB receptor subtype-specific compounds or CB-receptor-deficient mice.
Spasticity in patients with multiple sclerosis can be very difficult to control despite the use of oral baclofen, dantrolene, diazepam and tizanidine, continuous intrathecal baclofen infusion, and selective injection of botulinum toxin20. There is a need for more effective oral or systemic antispasticity agents. The hydrophobic nature of cannabinoids allows their rapid access to the CNS. Although the effects of chronic administration and dose dependency of CB receptor agonists on experimental spasticity remain to be investigated further, the data presented here provide evidence for the rational assessment of cannabinoid derivatives in the control of spasticity and tremor in multiple sclerosis, in placebo-controlled trials. The observation that CB1 appears to be the main therapeutic target suggests that it may be difficult to dissociate the full benefit from undesirable psychoactive elements using delta9-THC or cannabis. It is also consistent with the unpleasant side effects experienced by some patients at the doses required for potential therapy by existing cannabinoids3. The use of selective CB2 agonists may provide some symptomatic benefit without significant psychoactive effects. Furthermore, it may be possible to upregulate endogenous produced cannabinoids18 to mediate therapeutic benefit. This CREAE model provides a means of evaluating and controlling the pathophysiology of spasticity in a chronic inflammatory environment relevant to the control of multiple sclerosis.
MethodsInduction
of CREAE Biozzi ABH mice, bred at the Institute of Ophthalmology, were injected
with 1 mg of mouse spinal cord homogenate emulsified in Freund's complete adjuvant
on days 0 and 7 (ref. 1). Animals injected for CREAE, before the onset of acute
phase CREAE1 (usually occurring 15–20 days post inoculation (p.i.)) were
used as normal CREAE controls. Paralysed CREAE animals were selected during the
acute phase or first relapse (typically occurring 34–45 days p.i.), and remission
animals used for the assessment of tremor and spasticity were used after the second
or third relapse 40–80 days p.i.).
Chemicals
R(+)-WIN 55,212, S(-)-WIN 55,212, delta9-THC, methanandamide and cannabidiol were
purchased from RBI/Sigma (Poole, UK). Palmitoylethanolamide was purchased from
Tocris Cookson Ltd (Bristol, UK). SR141716A (ref. 15) and SR144528 (ref. 16) were
supplied by M. Mossé and F. Barth (Sanofi Research, Montpellier, France).
JWH-133 (3-(1'1'dimethylbutyl)-1-deoxy-delta 8-THC) was synthesised as described19.
All compounds were dissolved at 0.5 mg ml-1 in ethanol containing 1 mg ml-1 Tween
80 (Sigma). The ethanol was removed by vacuum drying, and samples were reconstituted
with phosphate buffered saline to a concentration of 2 mg ml-1. Similar preparations
without active drugs were used as vehicle controls. Suspensions (0.1 ml) were
injected either i.v. or i.p. after CREAE induction.
Assessment
of Clinical Signs Spasticity and tremor were initially assessed by blinded analysis
of video recordings. Digital images were sampled from video at 0.04 s. Signs of
tail spasticity (flicking and curling) were assessed visually as being either
present or absent. Spasticity was confirmed by assessing limb spasticity against
a small purpose-build strain gauge. Limbs of animals without clinical evidence
of spasticity (propensity to full extend the limb after tension on the leg) or
the propensity to cross were not examined in drug studies. The analogue signal
was amplified and digitally converted using an Amplicon card (Brighton, UK). This
was captured using dacquire V10 software (D. Buckwell, MRC HMBU, Institute of
Neurology) and analysed using Spike 2 software (Cambridge Electronic Design, UK).
The hindlimbs were fully extended twice then moved to full flexion against the
strain gauge. Each hindlimb was individually assessed by a blinded operator. The
mean of 4–8 individual readings per limb was taken. Tremor frequency and
severity were also recorded by holding the limb 5 mm above the strain gauge. Tremor
lead to the foot knocking the strain gauge. The strain gauge output was notch
filtered at 50 Hz. The device had a resonance frequency of 95 Hz. The frequency
of limb tremor was also confirmed using a lightweight unidirectional accelerometer
(EGA XT-50, Entrain, UK) mounted over the foot.
Statistical
Analysis Results are expressed as means of individual feet or animals s.e.m. per
group. The data were assessed using either a t-test, paired t-test for flexion
data or nonparametric Mann–Whitney U-test using SigmaStat 2.0 software (Jandel
Corp, San Rafael, California, USA).
Received
18 August 1999;accepted 20 January 2000
References
1.
Baker, D. et al. Induction of chronic relapsing experimental allergic
encephalomyelitis
in Biozzi mice. J. Neuroimmunol. 28, 261-270 (1990).
2.
Consroe, P., Musty,
R., Rein, J., Tillery, W. & Pertwee, R. The perceived
effects of smoked
cannabis on patients with multiple sclerosis. Eur. Neurol.
38, 44-48 (1997).
3.
Consroe,
P. Cannabinoid systems as targets for the therapy of neurological
disorders.
Neurobiol. Dis. 5, 534-551 (1998). Links
4.
Petro, D. J. & Ellenberger,
C. Treatment of human spasticity with 9-
tetrahydrocannabinol. J. Clin. Pharmacol.
21 (suppl.), 413-416 (1981).
5.
Clifford, D. B. Tetrahydrocannabinol for
tremor in multiple sclerosis. Ann.
Neurol. 13, 669-671 (1983). Links
6.
Ungerleider,
J. T., Andyrsiak, T., Fairbanks, L., Ellison, G. W. & Myers, L.
W. 9-THC
in the treatment of spasticity associated with multiple sclerosis.
Adv. Alcohol
Substance Abuse 7, 39-50 (1987).
7.
Martyn, C. N., Illis, L. S. & Thom,
J. Nabilone in the treatment of multiple
sclerosis. Lancet 345, 579 (1995).
Links
8.
Pertwee, R. G. Pharmacology of cannabinoid receptor ligands. Curr.
Med. Chem.
6, 635-664 (1999). Links
9.
Lyman, W. D., Sonett, J. R., Brosnan,
C. F., Elkin, R. & Bornstein, M. B.
9-tetrahydrocannabinol: a novel treatment
for experimental autoimmune
encephalomyelitis. J. Neuroimmunol. 23, 73-81 (1989).
Links
10.
Wirguin, I. et al. Suppression of experimental autoimmune encephalomyelitis
by
cannabinoids.
Immunopharmacology 28, 209-214 (1994). Links
11.
Heller, A. H. & Hallet,
M. Electrophysiological studies with the spastic
mutant mouse. Brain Res. 234,
299-308 (1982). Links
12.
Chai, C. K. Hereditary spasticity in mice. J.
Heredity 52, 241-243 (1961).
13.
Pertwee, R. G. Pharmacology of cannabinoid
CB1 and CB2 receptors. Pharmacol.
Therapeut. 74, 129-180 (1997).
14.Breivogel,
C. S. & Childers, S. R. The functional neuroanatomy of brain
cannabinoid
receptors. Neurobiol. Dis. 5, 417-431 (1998). Links
15.
Landsman, R. S.,
Burkey, T. H., Consroe, P., Roeske, W. R. & Yamamura, H.
I. SR141716A is
an inverse agonist at the human cannabinoid CB1 receptor.
Eur. J. Pharmacol.
334, R1-R2 (1997). Links
16.
Portier, M. et al. SR144528, an antagonist
for the peripheral cannabinoid
receptor that behaves as an inverse agonist.
J. Pharmacol Exp. Ther. 288,
582-589 (1999). Links
17.
Calignano, A.,
La Rana, G., Giuffrida, A. & Piomelli, D. Control of pain
initiation by
endogenous cannabinoids. Nature 394, 277-281 (1998). Links
18.
Giuffrida,
A. et al. Dopamine activation of endogenous cannabinoid signalling
in dorsal
striatum. Nature Neurosci. 2, 358-363 (1999). Links
19.
Huffman, J. W. et
al. 3-(1,1-Dimethylbutyl)-1-deoxy-9-THC and related compounds:
synthesis of
selective ligands for the CB2 receptor. Bioorg. Med. Chem. 7,
2905-2914 (1999).
Links
20.
Noth, J. Trends in the pathophysiology and pharmacotherapy of
spasticity. J.
Neurol. 238, 131-139 (1991). Links
Acknowledgements. The
authors would like to thank the Multiple Sclerosis
Society of Great Britain
and Northern Ireland, the Medical Research Council,
the National Institute
on Drug Abuse and the Wellcome Trust for their
financial support.
Nature
© Macmillan Publishers Ltd 2000 Registered No. 785998 England.